Bayer underlines potential of pipeline assets against backdrop of cell and gene ambitions

14 January 2021

German life sciences company Bayer (BAYN: DE) has made clear its long-term ambitions to be an industry leader in the field of cell and gene therapy.

But before that ambition can start to lead to major revenues, the Pharmaceuticals Division is betting on other pipeline assets to come good.

The company mentioned many of these as it outlined how it is driving forward its development portfolio during its virtual Pharma Media Day on Wednesday, outlining its work advancing more than 50 projects through the clinic in particular in cardiovascular diseases, oncology and women’s health.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK